Jun 19, 2025
Company highlights clinical findings on probiotics and postbiotics for gut health, metabolic balance, and cholesterol management
Ildong Bioscience, the health functional food subsidiary of Ildong Pharmaceutical Group, announced that it presented its latest research achievements at Probiota Americas 2025. The event took place in Vancouver, Canada, from June 9 to 11, marking its 10th anniversary as a leading global forum for scientific and industrial exchange in the microbiome sector.
As part of its participation, Ildong Bioscience hosted an exhibition booth to showcase its business activities and promoted its functional probiotic and postbiotic ingredients. In addition, the company presented three sets of research findings in poster format, focused on its proprietary strains and functional ingredients:
Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201)A clinical trial on patients with constipation-predominant irritable bowel syndrome (IBS-C) showed that an 8-week intake of RH 3201 significantly alleviated abdominal discomfort and bloating. The study also reported beneficial changes in the gut microbiota, including increases in Bacteroides cellulosilyticus and Akkermansia muciniphila, along with elevated levels of metabolites such as N-acetylornithine, xanthine, and 3-phenylpropionic acid—indicating improved gut environment and function.
Bifidobacterium lactis IDCC 4301Known for its anti-obesity potential, this strain was studied in both animal models and a 12-week human trial. Results showed significant reductions in body fat, abdominal fat, and serum triglyceride levels. Improvements were also observed in the leptin/adiponectin ratio, suggesting restored metabolic balance and enhanced energy metabolism.
Bifidobacterium breve IDCC 4401 Heat-Treated Culture (BBR 4401)A postbiotic recognized as an individually approved functional ingredient by the Korean Ministry of Food and Drug Safety, BBR 4401 demonstrated efficacy in both preclinical and human studies. Findings included reductions in LDL cholesterol and apolipoprotein B levels, suppression of hepatic fat accumulation, and increased bile acid excretion. In a 12-week human trial, BBR 4401 safely and significantly reduced LDL-C without notable adverse effects.
A representative from Ildong Bioscience stated, “This was a meaningful opportunity to reaffirm the company’s competitive edge in the microbiome sector, backed by differentiated strains, proprietary technologies, and strong R&D capabilities. Building on these research results, we plan to expand our portfolio of functional ingredients and accelerate market development both in Korea and overseas.”